Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in the heart of the life sciences hub of Basel area, Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea currently has about 150 employees and is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
View Top Employees from Basilea PharmaceuticaWebsite | http://basilea.com |
Ticker | BSLN |
Revenue | $75 million |
Employees | 201 (194 on RocketReach) |
Founded | 2000 |
Address | 487 Grenzacherstrasse, Basel, Bs 4005, CH |
Phone | +41 61 606 11 11 |
Fax | +41 61 606 11 12 |
Technologies |
JavaScript,
HTML,
Twitter
+24 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Healthcare, Science and Engineering, Drug Discovery, Commercial, Pharmaceutical, Health Care |
Web Rank | 6 Million |
Keywords | Biopharmaceuticals, Innovative Drug Development, Personalized Solutions |
Competitors | AiCuris Anti-infective Cures AG, Bio-Thera Solutions, CrystalGenomics, Inc., Nabriva Therapeutics plc, Otonomy, Inc |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325413 Companies |
Looking for a particular Basilea Pharmaceutica employee's phone or email?
The Basilea Pharmaceutica annual revenue was $75 million in 2024.
Gerrit Hauck is the CTO of Basilea Pharmaceutica.
194 people are employed at Basilea Pharmaceutica.
Basilea Pharmaceutica is based in Basel, Bs.
The NAICS codes for Basilea Pharmaceutica are [325, 3254, 32541, 32, 325413].
The SIC codes for Basilea Pharmaceutica are [28, 283].